Literature DB >> 15373900

Macrophages are a source of extracellular adenosine deaminase-2 during inflammatory responses.

B A Conlon1, W R Law.   

Abstract

Serum activity of the adenosine deaminase (ADA) isozyme, ADA2, has been reported to be elevated during various disease states. Macrophages have been suggested as the cellular source of extracellular ADA activity because they are one of the only cell types in which intracellular ADA2 activity has been measured, but extracellular secretion has never been demonstrated. Rat primary peritoneal macrophages (PPMs) and peripheral blood monocytes (PBMs) were harvested and incubated for 18 h in RPMI supplemented with horse serum. PPM and PBM lysates were assayed for intracellular ADA activity (ammonia production). In vitro and in vivo extracellular ADA activities were measured in media and rat serum, respectively. Activity of ADA1 was confirmed by selective inhibition with erythro-9-(2-hydroxy-3-nonyl) adenine (EHNA). ADA2 activity was inhibited by 2'-deoxycoformcin only, and was increased at a low pH (6.5). Activity of both ADA isozymes was found in PPMs and PBMs, and their media. In a separate group of rats, peritonitis was induced by ip insertion of 400 mg/kg caecal slurry. PPMs were harvested 24 h later and incubated for 18 h. In PPMs from rats with peritonitis both isozymes were elevated by a similar proportion. In contrast, media from these PPMs had a lower ADA1 and a higher ADA2 activity compared to PPMs from nonseptic rats. This resulted in a greater proportion of ADA2 in media. The isozyme proportions in serum from septic rats more closely resembled that of the PPM media. The response of PBM was small relative to that of PPM. These results suggest that macrophages are a significant source of extracellular ADA isozymes, the activity of which increases during an inflammatory response. Because extracellular isozymes profiles differ from cellular concentrations, the data also suggest differential release of each isozyme from PPMs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15373900      PMCID: PMC1809181          DOI: 10.1111/j.1365-2249.2004.02591.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  32 in total

1.  Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role.

Authors:  C Gakis
Journal:  Eur Respir J       Date:  1996-04       Impact factor: 16.671

Review 2.  Adenosine deaminase deficiency: molecular basis and recent developments.

Authors:  R Hirschhorn
Journal:  Clin Immunol Immunopathol       Date:  1995-09

3.  Determination of adenosine deaminase activity and its isoenzymes for diagnosis of pleural effusions.

Authors:  M Gorguner; M Cerci; I Gorguner
Journal:  Respirology       Date:  2000-12       Impact factor: 6.424

4.  Inhibiting adenosine deaminase modulates the systemic inflammatory response syndrome in endotoxemia and sepsis.

Authors:  Simon Adanin; Igor V Yalovetskiy; Beth A Nardulli; Albert D Sam; Zivojin S Jonjev; William R Law
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-05       Impact factor: 3.619

5.  Therapeutic potential for transient inhibition of adenosine deaminase in systemic inflammatory response syndrome.

Authors:  William R Law; Victor E Valli; Beth A Conlon
Journal:  Crit Care Med       Date:  2003-05       Impact factor: 7.598

6.  Adenosine deaminase inhibition attenuates microvascular dysfunction and improves survival in sepsis.

Authors:  Elliott S Cohen; William R Law; Cordus R Easington; Kenneth Q Cruz; Beth A Nardulli; Robert A Balk; Joseph E Parrillo; Steven M Hollenberg
Journal:  Am J Respir Crit Care Med       Date:  2002-07-01       Impact factor: 21.405

7.  Differential expression of adenosine deaminase isozymes in acute leukemia.

Authors:  H Ratech; F Martiniuk; W Z Borer; H Rappaport
Journal:  Blood       Date:  1988-11       Impact factor: 22.113

8.  Isolation of mutant adenosine deaminase by coformycin affinity chromatography.

Authors:  M J Danton; M S Coleman
Journal:  Anal Biochem       Date:  1986-11-15       Impact factor: 3.365

Review 9.  Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2.

Authors:  C Gakis; G Calia; A Naitana; D Pirino; G Serru
Journal:  Panminerva Med       Date:  1989 Jul-Sep       Impact factor: 5.197

10.  Cisplatin up-regulates the adenosine A(1) receptor in the rat kidney.

Authors:  Satyanarayan G Bhat; Snigdha Mishra; Yun Mei; Zhongzhen Nie; Craig A Whitworth; Leonard P Rybak; Vickram Ramkumar
Journal:  Eur J Pharmacol       Date:  2002-05-10       Impact factor: 4.432

View more
  17 in total

1.  Neuroinflammation after neonatal hypoxia-ischemia is associated with alterations in the purinergic system: adenosine deaminase 1 isoenzyme is the most predominant after insult.

Authors:  Victor Camera Pimentel; Maria Beatriz Moretto; Mariana Colino Oliveira; Daniela Zanini; Ana Maria Sebastião; Maria Rosa Chitolina Schetinger
Journal:  Mol Cell Biochem       Date:  2015-02-27       Impact factor: 3.396

2.  Protective effect of quercetin in ecto-enzymes, cholinesterases, and myeloperoxidase activities in the lymphocytes of rats exposed to cadmium.

Authors:  Fátima Husein Abdalla; Andréia Machado Cardoso; Roberta Schmatz; Jamile Fabbrin Gonçalves; Jucimara Baldissarelli; Caroline Curry Martins; Daniela Zanini; Lizielle Souza de Oliveira; Pauline da Costa; Victor Camera Pimentel; Luciane Belmonte Pereira; Cibele Lima Lhamas; Maria Rosa Chitolina Schetinger; Vera Maria Morsch; Cinthia Melazzo Andrade Mazzanti
Journal:  Mol Cell Biochem       Date:  2014-07-27       Impact factor: 3.396

3.  Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity.

Authors:  Andrey V Zavialov; Ake Engström
Journal:  Biochem J       Date:  2005-10-01       Impact factor: 3.857

4.  Assessment of uric acid and lipid peroxidation in serum and urine after hypoxia-ischemia neonatal in rats.

Authors:  V C Pimentel; F V Pinheiro; M Kaefer; R N Moresco; M B Moretto
Journal:  Neurol Sci       Date:  2010-08-21       Impact factor: 3.307

5.  Serum adenosine deaminase activity in patients with systemic lupus erythematosus: a study based on ADA1 and ADA2 isoenzymes pattern.

Authors:  Reza Saghiri; Niloufar Ghashghai; Shafieh Movaseghi; Pegah Poursharifi; Shohreh Jalilfar; Manijeh Ahmadi Bidhendi; Leila Ghazizadeh; Mina Ebrahimi-Rad
Journal:  Rheumatol Int       Date:  2011-02-25       Impact factor: 2.631

6.  Activation of CECR1 in M2-like TAMs promotes paracrine stimulation-mediated glial tumor progression.

Authors:  Changbin Zhu; Dana Mustafa; Ping-Pin Zheng; Marcel van der Weiden; Andrea Sacchetti; Maarten Brandt; Ihsan Chrifi; Dennie Tempel; Pieter J M Leenen; Dirk Jan Duncker; Caroline Cheng; Johan M Kros
Journal:  Neuro Oncol       Date:  2017-05-01       Impact factor: 12.300

Review 7.  New players driving inflammation in monogenic autoinflammatory diseases.

Authors:  Fabio Martinon; Ivona Aksentijevich
Journal:  Nat Rev Rheumatol       Date:  2014-09-23       Impact factor: 20.543

8.  Butyrylcholinesterase and γ-glutamyltransferase activities and oxidative stress markers are altered in metabolic syndrome, but are not affected by body mass index.

Authors:  Karine S De Bona; Gabriela Bonfanti; Paula E R Bitencourt; Lariane O Cargnelutti; Priscila S da Silva; Leidiane De Lucca; Victor C Pimentel; Etiane Tatsch; Thissiane L Gonçalves; Melissa Premaor; Rafael N Moresco; Maria Beatriz Moretto
Journal:  Inflammation       Date:  2013-12       Impact factor: 4.092

9.  Expression of Drosophila adenosine deaminase in immune cells during inflammatory response.

Authors:  Milena Novakova; Tomas Dolezal
Journal:  PLoS One       Date:  2011-03-11       Impact factor: 3.240

10.  The adenosine deaminase inhibitor erythro-9-[2-hydroxyl-3-nonyl]-adenine decreases intestinal permeability and protects against experimental sepsis: a prospective, randomised laboratory investigation.

Authors:  Nalan Kayhan; Benjamin Funke; Lars Oliver Conzelmann; Harald Winkler; Stefan Hofer; Jochen Steppan; Heinfried Schmidt; Hubert Bardenheuer; Christian-Friedrich Vahl; Markus A Weigand
Journal:  Crit Care       Date:  2008-10-13       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.